Literature DB >> 6846159

Nifedipine tablets for systemic hypertension: a study using continuous ambulatory intraarterial recording.

R S Hornung, B A Gould, R I Jones, T N Sonecha, E B Raftery.   

Abstract

The action of nifedipine tablets was examined in 17 patients with essential hypertension focusing particularly on the profile of blood pressure (BP) reduction over 24 hours resulting from both twice-daily and once-daily therapy (dose range 40 to 120 mg daily). This new formulation of nifedipine has a more prolonged and lower peak plasma level than an equivalent dose of nifedipine capsules. Our patients were fully ambulant and studied by continuous intraarterial recording techniques. BP responses during isometric and dynamic exercise testing were also observed. Within-patient comparisons of consecutive mean hourly systolic and diastolic BP showed a highly significant effect from twice-daily therapy (p less than 0.001) for nearly the entire day. Also, significantly lower BP was maintained during isometric and dynamic exercise. Mean hourly heart rates were not significantly altered. The profile of action of the single morning dose was initially similar, but its efficacy diminished from 6 P.M. to 8 A.M. on the following day. Side effects were not unduly troublesome and did not cause any patient withdrawals. Four patients developed mild ankle edema. Two others had facial flushing. Nifedipine given twice daily in tablet form, therefore, is an effective antihypertensive drug capable of lowering BP consistently over 24 hours in ambulant patients and during formal exercise testing. We suggest that this agent may be useful as initial therapy for systemic hypertension, although the tablets are not as yet widely available.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846159     DOI: 10.1016/0002-9149(83)90306-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Long-term therapy with slow-release nifedipine in essential hypertension.

Authors:  F Arrigo; F Consolo
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

4.  Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine.

Authors:  P A Broadhurst; G Brigden; M Heber; A Lahiri; E B Raftery
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 5.  Calcium antagonists and chronic cardiac failure.

Authors:  M J Kendall; R C Horton; S R Smith
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 6.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

7.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris.

Authors:  N S Khurmi; C W Robinson; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.

Authors:  K P Ohman; L Weiner; H von Schenck; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.